AI eye screening for AMD and diabetic retinopathy
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests an AI program called VeriSee that helps doctors check for eye problems like age-related macular degeneration (AMD) and diabetic retinopathy (DR). It compares the AI's accuracy and costs to standard care in regular eye clinics.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older and visiting a general eye clinic (not a retina specialist) for age-related macular degeneration screening.
- OR you are 20 years or older, have diabetes, and are visiting a general eye clinic for diabetic retinopathy screening.
- You agree to take part in the study and give your permission (informed consent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if an AI tool can help detect diabetic retinopathy and age-related macular degeneration in older adults visiting family medicine or geriatric clinics. It aims to catch these eye conditions early, before they cause vision loss.
This study uses an artificial intelligence (AI) tool to analyze eye images in people with type 2 diabetes. The goal is to see if the AI can help detect early signs of diabetic eye disease, so you can get the right care sooner.
This trial tests an AI system designed to catch early signs of late age-related macular degeneration (AMD) before it's diagnosed. It's for people who haven't yet been diagnosed with AMD or treated for retinal disease.
This trial uses artificial intelligence to analyze eye images and help doctors diagnose eye diseases. It looks at images from routine care to train and test the AI system.
This trial is testing an automated tool that helps screen for diabetic retinopathy, a complication of diabetes that affects the eyes. The goal is to see if the tool can accurately detect the condition, which may help with early treatment and prevent vision loss.
This trial tests a new AI-powered, do-it-yourself screening system for diabetic retinopathy. It may help find early signs of eye disease in people who haven't had an eye exam in the past year.
Hear when a new Age-Related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.